All In Biotech

Drug Trial Radar · NCT00351910

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major Depressive Disorder With Inadequate Response to an Antidepressant Treatment

Last checked: Nov 20, 2026Latest source record: Jan 26, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 494 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

494

Actual

Start

May 2006

Primary completion

Not stated

Study completion Apr 2007

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 13, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of quetiapine fumarate sustained release (Seroquel SR™) in combination with an antidepressant versus an antidepressant alone in patients with Major Depressive Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Conditions

  • Major Depressive Disorder

Interventions

  • QuetiapineDrug

  • AmitriptylineDrug

  • BupropionDrug

  • CitalopramDrug

  • DuloxetineDrug

  • EscitalopramDrug

  • FluoxetineDrug

  • ParoxetineDrug

  • SertralineDrug

  • VenlafaxineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of quetiapine fumarate sustained release
  2. (Seroquel SR™) in combination with an antidepressant versus an antidepressant alone in patients with Major Depressive Disorder.

Locations

72 sites in 12 countries. Site status is shown where the registry gives one.

  • Research Site

    Brisbane, Australia

  • Research Site

    Everton Park, Queensland, Australia

  • Research Site

    Southport, Queensland, Australia

  • Research Site

    Frankston, Victoria, Australia

  • Research Site

    Malvern, Victoria, Australia

  • Research Site

    Prahran, Victoria, Australia

  • Research Site

    Richmond, Victoria, Australia

  • Research Site

    Assebroek, Belgium

  • Research Site

    Brussels, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Kortrijk, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Mechelen, Belgium

  • Research Site

    Tielt, Belgium

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Moncton, New Brunswick, Canada

  • Research Site

    Mount Pearl, Newfoundland and Labrador, Canada

  • Research Site

    St. John's, Newfoundland and Labrador, Canada

  • Research Site

    Halifax, Nova Scotia, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Pointe-Claire, Quebec, Canada

  • Research Site

    Brno, Czechia

  • Research Site

    Havířov, Czechia

  • Research Site

    Havlíčkův Brod, Czechia

  • Research Site

    Nové Město nad Metují, Czechia

  • Research Site

    Olomouc, Czechia

  • Research Site

    Ostrava, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Helsinki, Finland

  • Research Site

    Jarvenpaa, Finland

  • Research Site

    Salo, Finland

  • Research Site

    Turku, Finland

  • Research Site

    Angoulême, France

  • Research Site

    Arcachon, France

  • Research Site

    Caen, France

  • Research Site

    Château-Gontier, France

  • Research Site

    Élancourt, France

  • Research Site

    Le Pecq, France

  • Research Site

    Nîmes, France

  • Research Site

    Paris, France

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.